Twice weekly vindesine, a phase II study in lung cancer.
Vindesine 1.75 mg/m2, twice weekly for 2 weeks followed by 2 weeks rest, was given to 26 lung cancer patients. In 6 patients a partial response was seen (23%). Neurotoxicity was present in 15 patients after 1 course; in 6 patients this was the reason for stopping therapy. This regimen has no advantage over weekly vindesine.
D004334:Drug Administration Schedule; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced; D008175:Lung Neoplasms / Q000188:drug therapy*; D014751:Vindesine / Q000008:administration & dosage* / Q000009:adverse effects
D014751:Vindesine